Zoetis Inc. (NYSE:ZTS) ranks among the best medical stocks to buy according to analysts. With a price target of $210, Piper ...

Zoetis, Inc. ZTS is expected to beat expectations when it reports its second-quarter 2025 earnings on Aug. 5, 2025, before ...

Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Zoetis Inc. (NYSE:ZTS) stands out ...

Trading volume stands at 1,715,669, with ZTS's price down by -0.4%, positioned at $145.2. RSI indicators show the stock to be may be approaching oversold. Earnings announcement expected in 4 days. 1 ...

Wedgewood Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter ...

In the latest trading session, Zoetis (ZTS) closed at $151.19, marking a +2.59% move from the previous day. The stock's ...

Zoetis Inc. Annual stock financials by MarketWatch. View the latest ZTS financial statements, income statements and financial ratios.

Here's why now is the time to consider buying three of my favorite S&P 500 dividend stocks on the dip, while their shares are currently down between 19% and 26% from their highs.

Zoetis (ZTS) ended the recent trading session at $148.81, demonstrating a -1.46% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.13%.

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.